Anika Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Anika Therapeutics (ANIK).

Price Target Range — 11 Quarters

Analyst Consensus — 2 Analysts

2Buy

Consensus RatingBuy# Analysts2Avg. Consensus PT$21Upside to Avg. PT+2.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 18, 2026	B. Riley Securities	Madison El-Saadi	Assumes	Buy	$21→$23
Jul 30, 2026	B. Riley Securities	Anderson Schock	PT Raise	Buy	$18→$21
Feb 27, 2026	Barrington Research	Michael Petusky	PT Raise	Outperform	$16→$17
Jan 9, 2026	Barrington Research	Michael Petusky	Maintained	Outperform	$16
Nov 6, 2025	Barrington Research	Michael Petusky	PT Raise	Outperform	$15→$16
Sep 23, 2025	Barrington Research	Michael Petusky	Maintained	Outperform	$15
Jul 31, 2025	Barrington Research	Michael Petusky	PT Cut	Outperform	$19→$15
May 12, 2025	Barrington Research	Michael Petusky	PT Cut	Outperform	$20→$19
Mar 13, 2025	Barrington Research	Michael Petusky	PT Cut	Outperform	$25→$20
Nov 1, 2024	Barrington Research	Michael Petusky	PT Cut	Outperform	$37→$25
Oct 22, 2024	Barrington Research	Michael Petusky	Maintained	Outperform	$37
Aug 9, 2024	Barrington Research	Michael Petusky	Maintained	Outperform	$37
May 29, 2024	Stephens & Co.	George Sellers	Maintained	Equal-Weight	$24
May 9, 2024	Barrington Research	Michael Petusky	Maintained	Outperform	$37
Mar 14, 2024	Stephens & Co.	George Sellers	Maintained	Equal-Weight	$22
Mar 14, 2024	Barrington Research	Michael Petusky	PT Raise	Outperform	$29→$37
Jan 3, 2024	Barrington Research	Michael Petusky	PT Raise	Outperform	$28→$29
Nov 3, 2023	Barrington Research	Michael Petusky	PT Raise	Outperform	$24→$28

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

B. Riley Securities analyst Madison El-Saadi assumes Anika Therapeutics (NASDAQ:ANIK) with a Buy rating and raises Price Target to $23.

Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

B. Riley Securities analyst Anderson Schock maintains Anika Therapeutics (NASDAQ:ANIK) with a Buy and raises the price target from $18 to $21.

Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and maintains $16 price target.

Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and raises the price target from $15 to $16.

Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and maintains $15 price target.

Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $15

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and lowers the price target from $19 to $15.

Benzinga Newsdesk

Anika Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Anika Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

PRO
B. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $15

People Also Watch

People Also Watch

Anika Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Anika Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROB. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

PROB. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

PROBarrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target

PROBarrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16

PROBarrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target

PROBarrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $15

People Also Watch

People Also Watch

PRO
B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

PRO
B. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target

PRO
Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $15